Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples